Edgewise Therapeutics Inc (EWTX)
27.72
+0.69
(+2.55%)
USD |
NASDAQ |
Jan 03, 16:00
27.66
-0.06
(-0.22%)
After-Hours: 20:00
Edgewise Therapeutics SG&A Expense (Quarterly): 8.21M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 371.80M |
| Catalyst Pharmaceuticals Inc | 45.88M |
| Sarepta Therapeutics Inc | 128.20M |
| Regenxbio Inc | 19.42M |
| Entrada Therapeutics Inc | 9.971M |